Intercept Pharmaceut (ICPT) 150.66 $ICPT
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
GlobeNewswire - Thu Jun 09, 4:35PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009. Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership.
ICPT: 150.66 (-3.56)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)
Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
ICPT: 150.66 (-3.56)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)
Intercept's (ICPT) Liver Dug Ocaliva Approved by the FDA
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:46AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA has granted accelerated approval to Ocaliva (obeticholic acid), in combination with ursodeoxycholic (UDCA).
ANIP: 52.05 (-1.64), PFE: 35.29 (-0.02), ICPT: 150.66 (-3.56), BMY: 72.65 (-0.08)
FDA Grants Accelerated Approval to Ocaliva(TM) (Obeticholic Acid) for the Treatment of Patients with PBC
GlobeNewswire - Fri May 27, 10:42PM CDT
First new medicine for PBC in nearly 20 years
ICPT: 150.66 (-3.56)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 91.49 (-1.00), HZNP: 17.88 (-0.65), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), ACOR: 27.07 (-0.45), BIOD: 0.34 (unch), XNPT: 7.00 (unch)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 3.05 (-0.08), RARE: 61.58 (-4.27), ICPT: 150.66 (-3.56), JUNO: 42.98 (-2.55)
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"
, a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee.
MDGN: 6.34 (+0.08), ICPT: 150.66 (-3.56), ADAP: 9.34 (+0.17)
Intercept Announces Ocaliva(TM) (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
GlobeNewswire - Wed May 18, 10:00AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at Digestive Disease Week (DDW) in San Diego, California from May 21-24, 2016. OCA is an investigational product and has not been granted marketing authorization or approval from any regulatory authority.
ICPT: 150.66 (-3.56)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 177.10 (-6.85), ICPT: 150.66 (-3.56), BIOD: 0.34 (unch), NKTR: 15.80 (-0.48)
Intercept Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Thu May 05, 3:07PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today reported financial results for the quarter ended March 31, 2016 and provided other general business updates. Intercept will hold a conference call and audio webcast today at 5:00 p.m. Eastern Time to review this information with conference call details provided below.
ICPT: 150.66 (-3.56)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.40 (-0.47), BIIB: 246.13 (-4.33), CNAT: 2.02 (-0.11), AMGN: 154.78 (-2.00), RPRX: 1.70 (-0.08), JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), GWPH: 89.69 (+0.24), GERN: 2.77 (-0.04), AVEO: 1.03 (-0.03), ICPT: 150.66 (-3.56), AGIO: 50.35 (-5.87), NVS: 78.94 (-1.57)
Intercept (ICPT): Stock Likely to Disappoint in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:43AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report first-quarter 2016 results on May 5, after the market closes.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), XON: 25.27 (+0.14), ICPT: 150.66 (-3.56)
Intercept to Report First Quarter 2016 Financial Results on May 5
GlobeNewswire - Thu Apr 28, 3:45PM CDT
Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report first quarter 2016 financial results after the NASDAQ Market closes on Thursday, May 5, 2016. Intercept management will conduct a conference call and webcast on Thursday, May 5, 2016 at 5:00 p.m. ET to discuss these results.
ICPT: 150.66 (-3.56)
Intercept Announces Winners of Practice to Policy Health Awards Program to Encourage New Research and Improve Care for People Living with PBC
GlobeNewswire - Sat Apr 16, 6:00AM CDT
Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the winners of its Practice to Policy Health Awards Program. Practice to Policy offers financial support to local and national projects in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), that create valuable insights, evidence and learning for the wider healthcare community across Europe, the United States and Canada. The winners were announced at the International Liver Congress 2016 of the European Association for the Study of the Liver (EASL, 13-17 April 2016).
ICPT: 150.66 (-3.56)
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.35 (-0.01), EBS: 42.30 (-1.19), ICPT: 150.66 (-3.56), AMAG: 21.04 (-0.82)
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
CLVS: 14.11 (-1.12), RLYP: 19.34 (+0.48), HZNP: 17.88 (-0.65), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25)
New Analyses of the Phase 3 POISE Trial of Ocaliva(TM) (Obeticholic Acid) for the Treatment of PBC Presented at EASL
GlobeNewswire - Thu Apr 14, 6:00AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the results of two new analyses of the POISE trial, the Phase 3 trial of Ocaliva (obeticholic acid) for the treatment of primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC). The analyses, presented at the International Liver Congress 2016, the 51st Annual Meeting of the European Association for the Study of the Liver (EASL), examined a risk model to predict estimated liver transplant-free survival of patients in the POISE trial and assessed a titration strategy for managing treatment-related pruritus. Ocaliva is an investigational product and has not been granted marketing authorization or approval from any regulatory authority.
ICPT: 150.66 (-3.56)
Biotech Stock Roundup: FDA Advisory Panels Say Yes to Intercept, No to Clovis
Arpita Dutt - Zacks Investment Research - Wed Apr 13, 9:02AM CDT
A couple of experimental drugs were reviewed by the FDA's advisory panels with a positive outcome for Intercept (ICPT) while Clovis (CLVS) faces a possible delay in gaining approval for its drug.
VRTX: 91.49 (-1.00), CLVS: 14.11 (-1.12), RLYP: 19.34 (+0.48), HZNP: 17.88 (-0.65), ALXN: 135.61 (-2.63), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25)
Intercept Pharmaceuticals Appoints Sandip Kapadia as Chief Financial Officer
GlobeNewswire - Thu Jun 09, 4:35PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the appointment of Sandip Kapadia as Chief Financial Officer. Mr. Kapadia will succeed Barbara Duncan effective July 1, who has served as CFO for Intercept since 2009. Ms. Duncan and Mr. Kapadia will work closely through a transition period to support a seamless change in leadership.
ICPT: 150.66 (-3.56)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 246.13 (-4.33), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)
Intercept to Present at Upcoming Investor Conferences
GlobeNewswire - Wed Jun 01, 3:05PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced management will be participating in the following investor conferences:
ICPT: 150.66 (-3.56)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 246.13 (-4.33), VRTX: 91.49 (-1.00), GILD: 84.45 (-1.32), SRPT: 19.95 (-1.04), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), IONS: 21.75 (+0.30)
Intercept's (ICPT) Liver Dug Ocaliva Approved by the FDA
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:46AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA has granted accelerated approval to Ocaliva (obeticholic acid), in combination with ursodeoxycholic (UDCA).
ANIP: 52.05 (-1.64), PFE: 35.29 (-0.02), ICPT: 150.66 (-3.56), BMY: 72.65 (-0.08)
FDA Grants Accelerated Approval to Ocaliva(TM) (Obeticholic Acid) for the Treatment of Patients with PBC
GlobeNewswire - Fri May 27, 10:42PM CDT
First new medicine for PBC in nearly 20 years
ICPT: 150.66 (-3.56)
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 91.49 (-1.00), HZNP: 17.88 (-0.65), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25), ACOR: 27.07 (-0.45), BIOD: 0.34 (unch), XNPT: 7.00 (unch)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 3.05 (-0.08), RARE: 61.58 (-4.27), ICPT: 150.66 (-3.56), JUNO: 42.98 (-2.55)
Adaptimmune Strengthens Board with Appointment of Barbara Duncan
GlobeNewswire - Tue May 24, 6:30AM CDT
Adaptimmune Therapeutics plc (Nasdaq:ADAP) ("Adaptimmune" or the "Company"
, a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee. MDGN: 6.34 (+0.08), ICPT: 150.66 (-3.56), ADAP: 9.34 (+0.17)
Intercept Announces Ocaliva(TM) (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
GlobeNewswire - Wed May 18, 10:00AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, announced today that five abstracts evaluating obeticholic acid (OCA) in patients with primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) will be presented at Digestive Disease Week (DDW) in San Diego, California from May 21-24, 2016. OCA is an investigational product and has not been granted marketing authorization or approval from any regulatory authority.
ICPT: 150.66 (-3.56)
Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Lag
Zacks Equity Research - Zacks Investment Research - Fri May 06, 2:59PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $3.33 per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of $3.58 but wider than the year-ago loss of $1.78.
SHPG: 177.10 (-6.85), ICPT: 150.66 (-3.56), BIOD: 0.34 (unch), NKTR: 15.80 (-0.48)
Intercept Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Thu May 05, 3:07PM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today reported financial results for the quarter ended March 31, 2016 and provided other general business updates. Intercept will hold a conference call and audio webcast today at 5:00 p.m. Eastern Time to review this information with conference call details provided below.
ICPT: 150.66 (-3.56)
Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.40 (-0.47), BIIB: 246.13 (-4.33), CNAT: 2.02 (-0.11), AMGN: 154.78 (-2.00), RPRX: 1.70 (-0.08), JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), GWPH: 89.69 (+0.24), GERN: 2.77 (-0.04), AVEO: 1.03 (-0.03), ICPT: 150.66 (-3.56), AGIO: 50.35 (-5.87), NVS: 78.94 (-1.57)
Intercept (ICPT): Stock Likely to Disappoint in Q1 Earnings
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:43AM CDT
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report first-quarter 2016 results on May 5, after the market closes.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), XON: 25.27 (+0.14), ICPT: 150.66 (-3.56)
Intercept to Report First Quarter 2016 Financial Results on May 5
GlobeNewswire - Thu Apr 28, 3:45PM CDT
Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that it will report first quarter 2016 financial results after the NASDAQ Market closes on Thursday, May 5, 2016. Intercept management will conduct a conference call and webcast on Thursday, May 5, 2016 at 5:00 p.m. ET to discuss these results.
ICPT: 150.66 (-3.56)
Intercept Announces Winners of Practice to Policy Health Awards Program to Encourage New Research and Improve Care for People Living with PBC
GlobeNewswire - Sat Apr 16, 6:00AM CDT
Intercept Pharmaceuticals Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the winners of its Practice to Policy Health Awards Program. Practice to Policy offers financial support to local and national projects in primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC), that create valuable insights, evidence and learning for the wider healthcare community across Europe, the United States and Canada. The winners were announced at the International Liver Congress 2016 of the European Association for the Study of the Liver (EASL, 13-17 April 2016).
ICPT: 150.66 (-3.56)
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 10:30AM CDT
Synta (SNTA) announced all-stock merger transaction with Madrigal Pharmaceuticals to create a company focused on cardiovascular-metabolic diseases and NASH.
SNTA: 0.35 (-0.01), EBS: 42.30 (-1.19), ICPT: 150.66 (-3.56), AMAG: 21.04 (-0.82)
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 8:30AM CDT
The Zacks Analyst Blog Highlights: Intercept, Clovis, AbbVie, Relypsa and Horizon Pharma
CLVS: 14.11 (-1.12), RLYP: 19.34 (+0.48), HZNP: 17.88 (-0.65), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25)
New Analyses of the Phase 3 POISE Trial of Ocaliva(TM) (Obeticholic Acid) for the Treatment of PBC Presented at EASL
GlobeNewswire - Thu Apr 14, 6:00AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced the results of two new analyses of the POISE trial, the Phase 3 trial of Ocaliva (obeticholic acid) for the treatment of primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC). The analyses, presented at the International Liver Congress 2016, the 51st Annual Meeting of the European Association for the Study of the Liver (EASL), examined a risk model to predict estimated liver transplant-free survival of patients in the POISE trial and assessed a titration strategy for managing treatment-related pruritus. Ocaliva is an investigational product and has not been granted marketing authorization or approval from any regulatory authority.
ICPT: 150.66 (-3.56)
Biotech Stock Roundup: FDA Advisory Panels Say Yes to Intercept, No to Clovis
Arpita Dutt - Zacks Investment Research - Wed Apr 13, 9:02AM CDT
A couple of experimental drugs were reviewed by the FDA's advisory panels with a positive outcome for Intercept (ICPT) while Clovis (CLVS) faces a possible delay in gaining approval for its drug.
VRTX: 91.49 (-1.00), CLVS: 14.11 (-1.12), RLYP: 19.34 (+0.48), HZNP: 17.88 (-0.65), ALXN: 135.61 (-2.63), ICPT: 150.66 (-3.56), ABBV: 61.00 (+0.25)
